This was the stock's third consecutive day of losses.

IQVIA Holdings Inc. closed 42.44% below its 52-week high of $252.88, which the company reached on August 29th.

BofA lowered the firm’s price target on Iqvia (IQV) to $190 from $235 and keeps a Buy rating on the shares. Sentiment for Life Sciences and ...

The IQVIA Institute for Human Data Science has released, Global Trends in R&D 2025 report, Progress in Recapturing Momentum ...

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa ...

Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s ...

IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a ...

The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex ...

Barclays downgraded Iqvia (IQV) to Equal Weight from Overweight with a price target of $170, down from $235. The firm moved to the sidelines on ...

Abbott in collaboration with IQVIA highlights that 44% of people have been living with vertigo for more than a year, experiencing episodes once a week. Many mistake vertigo for low blood sugar, low ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...